Suitability depends on patient location, clinician licensure, health history, current regulations, and whether an examination, vital signs, laboratory testing, or in-person service is required
A solution that remains hazy after adequate time to fully dissolve, or that develops visible particles after a period in storage, should not be used in an active protocol
However, the optimal wearing time would be determined by the specific product design, drug formulation, and delivery technology, and would be clearly specified in any future product's Patient Information Leaflet (PIL) if approved
Administration Both Tirzepatide and Semaglutide are administered via subcutaneous injection, typically once a week
Carbonated drinks, alcohol, spicy foods, fried foods and rich desserts can trigger nausea
Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease